Evidence Hub

Characteristics of invasive group B streptococcal infections in adults and older individuals in a super-aging society in Japan, 2016-2023

Takahashi H, Miyazaki H, Watanabe Y, Kawahata D, Nasu Y, Takata M, Nakaminami H, Watanabe H et al.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2026

Abstract

BACKGROUND: Group B Streptococcus (GBS), a commensal bacterium in the gastrointestinal tract, can cause invasive GBS (iGBS) infections, particularly in older adults with underlying comorbidities. We determined the relationship between mortality and host-related or virulence factors in older adults with iGBS infections.

METHODS: We retrospectively analyzed 105 cases of iGBS infection treated between January 2016 and October 2023 at Tokyo Medical University Hospital and two affiliated hospitals. The association between patient outcomes and demographics, underlying diseases, clinical manifestations, medical treatment, biomarkers, antimicrobial agents used at admission, and capsular type of GBS isolates was examined.

RESULTS: The median age of the patients was 78 years (interquartile range, 64-85 years), and 89.5 % had underlying comorbidities, such as diabetes, chronic kidney disease, and malignancies. Common clinical manifestations include skin and soft tissue infections, bacteremia, and urosepsis. The overall mortality rate was 11.4 %. White blood cell (WBC) counts (breakpoint,10 × 103/μL) on admission were significantly lower in fatal cases (P < 0.001; odds ratio, 9.6), but no significant differences were observed for other biomarkers. The Kaplan-Meier estimate of 28-day survival was associated with WBC count (P < 0.001). The most common capsular type was Ib, followed by type V. Levofloxacin resistance was predominantly identified in type Ib. No significant association was…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free